Cargando…

Genomic Prostate Score: A New Tool to Assess Prognosis and Optimize Radiation Therapy Volumes and ADT in Intermediate-Risk Prostate Cancer

SIMPLE SUMMARY: Current standard clinical risk-stratification systems do not sufficiently reflect the disease heterogeneity for prostate cancer. Intermediate risk prostate cancer represents a highly heterogeneous risk group with different treatment options available such as surgery, radiation therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Belkacemi, Yazid, Debbi, Kamel, Coraggio, Gabriele, Bendavid, Jérome, Nourieh, Maya, To, Nhu Hanh, Cherif, Mohamed Aziz, Saldana, Carolina, Ingels, Alexandre, De La Taille, Alexandre, Loganadane, Gokoulakrichenane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913491/ https://www.ncbi.nlm.nih.gov/pubmed/36765902 http://dx.doi.org/10.3390/cancers15030945

Ejemplares similares

Effect of Serelys Homme on the Incidence and Severity of Vasomotor Symptoms and Quality-of-Life Impairments in Patients Receiving Hormone Therapy and Radiation for Localized Prostate Cancer: Results of the ESCULAPE Phase 2 Prospective Study
por: Belkacemi, Yazid, et al.
Publicado: (2023)

Radiation Therapy Delivery Challenges in Older Patients During Coronavirus Disease 2019 Pandemic
por: Cherif, Mohamed Aziz, et al.
Publicado: (2020)

Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence
por: Debbi, Kamel, et al.
Publicado: (2023)

Complete response in anaplastic lymphoma kinase–rearranged oncocytic thyroid cancer: A case report and review of literature
por: de Salins, Victoire, et al.
Publicado: (2020)

Radiation Therapy Department Reorganization during the Coronavirus Disease 2019 (COVID-19) Outbreak: Keys to Securing Staff and Patients During the First Weeks of the Crisis and Impact on Radiation Therapy Practice from a Single Institution Experience
por: Belkacemi, Yazid, et al.
Publicado: (2020)

Pathologic Response to Neoadjuvant Sequential Chemoradiation Therapy in Locally Advanced Breast Cancer: Preliminary, Translational Results from the French Neo-APBI-01 Trial
por: To, Nhu Hanh, et al.
Publicado: (2023)

Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management
por: Courcier, Jean, et al.
Publicado: (2020)

Overexpression of Nucleolin and Associated Genes in Prostate Cancer
por: Firlej, Virginie, et al.
Publicado: (2022)

Neoadjuvant radiotherapy in triple-negative breast cancer: “the past should not steal the present or hide the future”
por: To, Nhu Hanh, et al.
Publicado: (2022)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
por: Uemura, Hiroji, et al.
Publicado: (2021)

Association between overweight, obesity, and quality of life of patients receiving an anticancer treatment for prostate cancer: a systematic literature review
por: Depotte, Léonard, et al.
Publicado: (2023)

Restaging the Biochemical Recurrence of Prostate Cancer with [(68)Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management
por: Fourquet, Aloÿse, et al.
Publicado: (2021)

The impact of hegemonic masculine ideals on self‐esteem in prostate cancer patients undergoing androgen deprivation therapy (ADT) compared to ADT‐naïve patients
por: Gentili, Caterina, et al.
Publicado: (2022)

The effect of strength training on muscle cellular stress in prostate cancer patients on ADT
por: Nilsen, T S, et al.
Publicado: (2016)

Transport of ADT
por: Juha Sakkinen
Publicado: (2006)

Timing of exercise for muscle strength and physical function in men initiating ADT for prostate cancer
por: Newton, Robert U., et al.
Publicado: (2020)

Severity of COVID-19 infection in prostate cancer patients and effect of ADT on disease presentation
por: García Fuentes, C., et al.
Publicado: (2021)

Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer
por: Nguyen, P L, et al.
Publicado: (2017)

Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis
por: Botrel, Tobias Engel Ayer, et al.
Publicado: (2016)

The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer
por: Lawrenson, Ross, et al.
Publicado: (2014)

International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries
por: Liede, Alexander, et al.
Publicado: (2016)

Financial fallout from the COVID-19 pandemic:Report from a high-volume academic neurosurgery
por: Loganadane, G., et al.
Publicado: (2022)

Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT
por: Ayoub, Zeina, et al.
Publicado: (2022)

ADT and OBSBOX in 2016
por: Valuch, D, et al.
Publicado: (2017)

Editorial on an international survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries
por: Sternberg, Cora N
Publicado: (2016)

Biochemical recurrence related metabolic novel signature associates with immunity and ADT treatment responses in prostate cancer
por: Wang, Xuan, et al.
Publicado: (2022)

Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer
por: Mahalingam, Devalingam, et al.
Publicado: (2023)

ADT fast losses MD
por: Priebe, A, et al.
Publicado: (2013)

Myokine Expression and Tumor-Suppressive Effect of Serum after 12 wk of Exercise in Prostate Cancer Patients on ADT
por: KIM, JIN-SOO, et al.
Publicado: (2022)

Palliative TURP Combined with Intermittent ADT Is A Curative Therapy to Some Elderly Men with Localized Prostate Adenocarcinoma
por: Zhang, Xu, et al.
Publicado: (2023)

Correction: Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer
por: Mahalingam, Devalingam, et al.
Publicado: (2023)

Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
por: Chowdhury, Simon, et al.
Publicado: (2019)

Hypothalamic connectivities predict individual differences in ADT-elicited changes in working memory and quality of life in prostate cancer patients
por: Chaudhary, Shefali, et al.
Publicado: (2022)

Does ADT Influence the Risk of Suicidal Ideation among US Veteran Prostate Cancer Patients Pre-Exposed to PTSD?
por: Brahmbhatt, Smit, et al.
Publicado: (2023)

Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancer
por: Kang, Ning, et al.
Publicado: (2023)

ADT and RF after LS1
por: Butterworth, A, et al.
Publicado: (2015)

Weniger Corona-Infektionen unter ADT?
por: Bublak, Robert
Publicado: (2020)

Bridging Arrays and ADTs in Recursive Proofs
por: Fedyukovich, Grigory, et al.
Publicado: (2021)

Extracellular Vesicles in Advanced Prostate Cancer: Tools to Predict and Thwart Therapeutic Resistance
por: Saldana, Carolina, et al.
Publicado: (2021)

Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration
por: Long, Xingbo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tbctp7701l8dlqf67pfuus1t4h